NCT00661700已完成3 期
A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 611
- 主要终点
- The primary efficacy comparison is EF domain of the IIEF, vardenafil preferred dose versus placebo at week 18 (after 4 weeks of preferred treatment).
研究概览
简要总结
To find out more information on how treating impotence with vardenafil in comparison to placebo affects the quality of life (QoL) of men and their partners. Subjects will receive 10mg vardenafil or placebo for 4 weeks followed by an 8 week period when the dose of vardenafil may be reduced to 5mg or increased to 20mg. Subjects will then receive their 'preferred' dose for 14 weeks. During this time Quality of Life Measures will be collected via questionnaires
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males with erectile dysfunction for more than six months according to the NIH Consensus Statement (the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance)
- •Stable, heterosexual relationship for more than six months
- •Documented written Informed Consent, from both the patient and his partner, after receiving adequate previous information and prior to any study specific procedures.
- •An ED-EQoL score < or = 15.- An IIEF score < or = 25.
排除标准
- •Presence of penile anatomical abnormalities (eg. penile fibrosis or Peyronie's disease) that would significantly impair erectile function.
- •History of radical prostatectomy. - Retinitis pigmentosa.
- •History of positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C.- Unstable angina pectoris.
- •History of myocardial infarction, stroke, electrocardiographic ischaemia (except stable angina), or life-threatening arrhythmia within the prior 6 months.
- •Atrial tachyarrhythmia (eg. atrial fibrillation/flutter) with a heart rate of >100 beats per minute at screening.
- •Child-Pugh class B liver disease or liver function abnormalities.
- •Clinically significant chronic haematological disease or bleeding disorder
- •History of significant peptic ulcer disease within one year before Visit 1
- •Resting hypotension (a resting systolic blood pressure of <90 mm Hg) or hypertension (a resting systolic blood pressure >170 mm Hg or a resting diastolic blood pressure >110 mm Hg).
- •Symptomatic postural hypotension within the six months of Visit
- •Uncontrolled diabetes mellitus (haemoglobin A1c > 12%).
- •Patients who are taking nitrates or nitric oxide donors (e.g. molsidomine).
- •Patients who are taking anticoagulants, with the exception of anti-platelet agents.
- •Patients who are taking androgens (e.g. testosterone), trazodone or anti-androgens.
- •Patients who are taking the following inhibitors of cytochrome P 450 CYP 3A4: potent HIV protease inhibitors (ritonavir, indinavir), the anti-mycotic agents itraconazole and ketoconazole (topical forms are allowed) or erythromycin.
研究组 & 干预措施
Arm 2
Placebo Comparator
干预措施: Placebo (Drug)
Arm 1
Experimental
干预措施: Levitra (Vardenafil, BAY38-9456) (Drug)
结局指标
主要结局
The primary efficacy comparison is EF domain of the IIEF, vardenafil preferred dose versus placebo at week 18 (after 4 weeks of preferred treatment).
时间窗: At week 18 (after 4 weeks of preferred treatment).
次要结局
- The relationship between the change from baseline score for; EF domain, SEP2, SEP3 and GEQ with that for ED-QoL and EDITS will be explored for the vardenafil 10mg and 20mg groups respectively(Baseline and at week 18 (after 4 weeks of preferred treatment).)
- Measurements and changes from baseline in vital signs (blood pressure and pulse rate), continuous laboratory variables,(Baseline and at weeks 4, 8, 12, 18 and 26)
- Global Assessment Question (GAQ) responses(At weeks 4, 8, 12, 18 and 26)
- Treatment groups will be compared with respect to the incidence rates of premature termination, adverse events, lab abnormalities, ECG abnormalities, and concomitant medication use(Baseline and at weeks 4, 8, 12, 18 and 26)
- Measurements and changes from baseline in vital signs (blood pressure and pulse rate), continuous laboratory variables, ECG cardiac cycle measurements, and ECG heart rate(Baseline and Week 26)
研究者
相似试验
已完成
3 期
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile DysfunctionErectile DysfunctionNCT00657033Bayer229
已完成
3 期
Study Evaluating the Efficacy, Safety, and Reliability of VardenafilErectile DysfunctionNCT00661297Bayer523
已完成
3 期
Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile DysfunctionErectile DysfunctionNCT00658177Bayer463
已完成
3 期
To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.Erectile DysfunctionNCT00661115Bayer173
已完成
2 期
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's SyndromeRaynaud SyndromeNCT01291199University of Cologne57